Incidence and risk factors for pre-eclampsia in Jos Nigeria

Jonah Musa¹, Caleb Mohammed², Amaka Ocheke³, Makswar Kahansim³, Victor Pam³, Patrick Daru³

1. University of Jos Faculty of Medical Sciences.
2. Kaduna State University Faculty of Medicine, Obstetrics and Gynaecology.
3. University of Jos Faculty of Medical Sciences, Obstetrics and Gynaecology.

Abstract

Objective: We sought to estimate the incidence and risk factors associated with development of pre-eclampsia (PET) in Jos, Nigeria.

Methods: An open cohort study of singleton pregnant women attending the antenatal clinic of Jos University Teaching Hospital (JUTH), Nigeria between November 2010 and August 2011. Eligible healthy women at ≤ 20 weeks gestation were enrolled and followed up until delivery or development of pre-eclampsia. Baseline demographic characteristics including weight, height and body mass index (BMI) were collected at enrollment. Incidence, risk factors and hazard ratios for developing PET were estimated with corresponding 95% confidence intervals and p-values. All statistical analyses were done with STATA version 11, college station, Texas, USA.

Results: A total of 2416 pregnant women were screened for eligibility out of which 323 were eligible for inclusion. The incidence of PET was 87.9 per 1,000 pregnancies (8.8%). The significant risk factors for PET were previous history of PET (RR=5.1, 95% CI: 2.2-12.1) and BMI at booking ≥ 25 kg/m² (RR=3.9, 95% CI: 1.5-10.0).

Conclusion: The incidence of PET was relatively high in our cohort in Jos, Nigeria and a previous history of the disease and overweight or obese pregnant women have a significant hazard of developing the disease in the course of gestational follow up. Targeting women with these characteristics for early preventive intervention and close surveillance at the antenatal booking clinic may help in prevention of the disease and its complications.

Keywords: Pre-eclampsia, incidence, risk, hazard, Jos Nigeria.

DOI: https://dx.doi.org/10.4314/ahs.v18i3.16


Introduction

Hypertensive disorders in pregnancy affects up to 8% of pregnancies¹ and are among the leading causes of maternal and neonatal morbidity and mortality worldwide, particularly in developing countries¹². The National Heart Lung and Blood Institute (NHLBI) working group on research on hypertension during pregnancy¹ defines pre-eclampsia as a clinical syndrome that occurs after mid-gestation (20th week of pregnancy), characterized by de novo appearance of systolic blood pressure ≥140 mm Hg or diastolic blood pressure of ≥90 mm Hg, accompanied by new-onset proteinuria, defined as ≥300 mg per 24 hours. Findings from a recent multicenter study in Nigeria showed that pre-eclampsia/eclampsia is a leading cause of significant maternal morbidity and mortality in Nigeria³ and ongoing efforts to improve maternal mortality in Nigeria focuses on capacity building to identify early
features of pre-eclampsia and addressing gaps in appropriate management of the condition during pregnancy. Since the etiology of pre-eclampsia is not well understood and trials on prevention have been disappointing, efforts at clinical prediction based on identifiable risk factors seems a sensible approach to surveillance and prevention of complications due to pre-eclampsia particularly in resource-limited settings. Indeed, delays in diagnosis and access to effective treatment are leading factors responsible for high maternal and perinatal mortality from pre-eclampsia. Additionally, studies have shown the significance of prediction, prevention, diagnosis and treatment among the evidence-based interventions for improving maternal and perinatal outcomes in pre-eclampsia and other hypertensive diseases during pregnancy. Clinical risk prediction research on the development of pre-eclampsia have focused on nulliparous pregnant women and identified risk factors measured at 14-16 weeks gestation including maternal age, mean arterial blood pressure, body mass index, family history of preeclampsia, family history of coronary heart disease and maternal birth weight. Other previously documented risk factors include systolic blood pressure at entry and pre-pregnancy obesity. However, most of these studies were done in countries outside of Africa and the generalizability of these findings to women in Nigerian settings may be limited.

This study was therefore done to provide data on incidence and risk factors that are predictive of pregnant women developing pre-eclampsia in an antenatal setting of a University Teaching Hospital in Jos, North-Central Nigeria, Africa. We believe these findings will contribute to the body of knowledge on the epidemiology of this disease and may provide valuable information for possible development of a screening check-list and algorithm for triaging booked antenatal clients for close surveillance in order to improve ability of antenatal care providers to diagnose pre-eclampsia early thereby minimizing risk of complications that could result in maternal and perinatal morbidity and mortality in Nigeria.

Methods

Design and setting

This prospective open-cohort study was conducted at the antenatal clinic of the Jos University Teaching Hospital, Jos Nigeria, a tertiary academic medical and referral center located in North-Central Nigeria. At the time of this study, the standard (traditional) model of antenatal care was operational i.e. 4 weekly visits for the first 28 weeks; 2 weekly visits until 36 weeks and weekly thereafter until delivery. Those who develop medical complications within the follow up period were admitted into the antenatal ward for specialized care.

Study population

All pregnant women presenting at the booking visit at ≤ 20 weeks of gestation estimated using the last normal menstruation date were screened for eligibility to participate in this study. The inclusion criteria were: 1. Normal blood pressure measurement at the booking visit (≤ 20 weeks of gestation), 2. Informed consent to participate in the study with indicated willingness to be followed up until delivery or development of the outcome. Those with significant proteinuria at booking, known hypertensive and high blood pressure readings at ≤ 20 weeks gestation were excluded from the study. Those who booked for antenatal care after the 20th week of gestation were excluded from the study. Women with chronic medical conditions such as kidney disease, Diabetes mellitus, Sickle cell anemia were excluded.

Participants’ enrollment and follow up

The study was open for enrollment from November 2010 to August, 2011. At enrollment, a detailed questionnaire was administered to each research participant to obtain data on age, parity, date of enrollment, gestational age at enrollment, educational background, smoking and alcohol history, previous abortions, age at marriage, history of infertility and previous history of pre-eclampsia. The booking blood pressure, qualitative urine protein status, weight, and height were also documented for each participant. Participant’s weight was measured using a standard scale (Seca manufactured by Vogel and Halke, Hamburg, Germany) to the nearest gram. The women were weighed fully clothed with shoes removed. Height was measured without shoes using a Stadiometer (Seca manufactured by Vogel and Halke, Hamburg, Germany) to the nearest centimeter. Urine protein was qualitatively measured using a dip stick (Uripath 2 brand manufactured by Antec diagnostics Limited- www.antecmedicalproducts.com) on a clean catch urine sample passed into a universal bottle. This was done by inserting
the dip stick into the urine and the result read after 60 seconds comparing it with the standards placed on the container of the dip stick. The possible readings were as follows: Negative, Trace, +(30mg/dl), ++ (100mg/dl), +++ (300mg/dl) and ++++(≥2000mg/dl). In this study, significant proteinuria was defined as qualitative urine protein of ++ or more (i.e 100mg/dl).

Blood pressure was measured with the patient seated on a chair. The non-dominant arm was supported at the level of the heart on a table ensuring that no tight clothing constricts the arm. The cuff of the mercury sphygmomanometer (Accoson brand) was placed on the arm with the center of the bladder over the brachial artery. The lower edge of the cuff was placed 2-3 cm above the point of the pulsation of the brachial artery. The bladder encircled at least 80% of the arm. The systolic blood pressure was estimated by palpating the radial artery and inflating the cuff until pulsation disappears. The cuff was then deflated and systolic blood pressure estimated. The sphygmomanometer was then inflated 30mmHg above the estimated systolic needed to occlude the pulse. A stethoscope diaphragm was then placed over the brachial artery and deflated at a rate of 2-3 mmHg/second until regular tapping sounds were heard. The systolic blood pressure was estimated at the level when the first sound was heard and diastolic blood pressure was estimated at the level when the sound muffled (Korotkoff phase IV) and these were measured to the nearest 2 mmHg. The follow ups were scheduled to fit into the routine standard antenatal care follow up protocol for the clinic. At each follow up visit, blood pressure, weight and urine protein estimations were repeated and documented for each patient. Follow up was terminated at any gestational age if the woman developed pre-eclampsia or delivery of her baby with or without development of pre-eclampsia.

**Primary outcome measure**
The primary outcome was diagnosis of pre-eclampsia as defined during the follow up time. The follow up time was the period in weeks between the gestational age at enrollment to development of the primary outcome or delivery of baby whichever came first).

**Data management and Statistical analysis**
All data collected were entered into an excel Microsoft 2003 template, and coded for relevant statistical analysis. Summary statistics were generated to compare baseline characteristics of women who developed PET to those who did not. We estimated the incidence of PET and the risk ratio of PET for various exposure variables and corresponding 95% confidence intervals and p-value were estimated. The risk ratio and incident rate ratio for the development of pre-eclampsia were comparable for all the exposure variables, so we reported risk ratio for easy interpretation. We also developed a Cox proportional hazard regression model using follow up time in gestational weeks as a time variable and development of PET as a failure variable to determine the hazard ratio for development of PET for various exposure variables. Variables with significant hazard ratio were subsequently included in a multivariate Cox regression model to determine independent factors associated with significant hazards for development of PET. Relevant Kaplan-Meier graphs were generated to estimate the cumulative incident probability of developing PET. The Log-Rank test was used to assess equality of failure estimates. P values <0.05 suggest significant differences in cumulative incident probability of developing PET. All statistical analyses were done using STATA version 11.0, College Station, Texas, USA. Statistical significance were based on 95% confidence interval and p value <0.05.

**Ethical approval**
The study protocol was approved by the Human Subjects Research Ethics Committee of the Jos University Teaching Hospital, Jos.

**Results**
During the 10 months study period (November 2010 to August, 2011), a total of 2416 pregnant women were screened for eligibility at the antenatal out-patient clinic of JUTH. A total of 323 pregnant women were enrolled and followed up during the study (Fig 1 shows study flow chart with details of enrollment). A total of 307 completed follow up and were included in the final analysis of incidence and risk factors for pre-eclampsia.
Socio-demographic characteristics of study participants
The median age of the cohort was 28 years with inter-quartile range (IQR) 25-31 years. The median parity and gestational age at booking were 1 (IQR, 0-3) and 15 weeks (IQR, 12-18) respectively. The median systolic and diastolic blood pressures at booking were 110mmHg (IQR, 110-120) and 70mmHg (IQR, 60-70) respectively. The median body weight and body mass index at booking were 63.5 kg (IQR, 55-74.5) and 25.2 kg/m² (IQR, 22.3-28.7) respectively. Other relevant socio-demographic characteristics of the study cohort were positive HIV status of 4.9% (95% CI: 2.4-7.3); Previous history of pre-eclampsia of 3.6% (95% CI: 1.5-5.7); previous history of miscarriage of 32.6% (95% CI: 26.6-38.4); and history of infertility of 8.4% (95% CI: 4.1-12.6). Almost all the study participants (99.3%) were married. Table 1. Shows baseline characteristics of the study participants who developed PET compared to those who did not develop PET in the cohort.
Incidence of preeclampsia

Twenty seven (27) out of the 307 normotensive women included in the study developed PET during the study period giving an incidence of 87.9 per 1,000 pregnancies (8.8%). The estimated 95% CI of the incidence was 56.5 -120.5 cases per 1,000 pregnancies booked at 20 weeks or lesser gestation.

Risk factors for development of pre-eclampsia

The significant risk factors for the development of pre-eclampsia in the cohort were previous history of pre-eclampsia (RR=5.1, 95% CI: 2.2-12.1) and BMI at booking of ≥ 25 kg/m² (RR=3.9, 95% CI: 1.5-10.0). Previous history of miscarriage, HIV infection, history of infertility and parity were not significant risk factors for the development of pre-eclampsia (Table 2 summarizes the point estimates of risk and the associated 95% confidence intervals and p-values).

Table 1: Baseline characteristics of study participants who developed PET compared with those who did not develop PET during the follow up period

<table>
<thead>
<tr>
<th>Variable</th>
<th>Developed PET</th>
<th>95% CI</th>
<th>Did not Developed PET</th>
<th>95% CI</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>29.7</td>
<td>28.4-31.0</td>
<td>28.4</td>
<td>27.8-28.9</td>
<td>0.1468</td>
</tr>
<tr>
<td>Gestational age at enrollment (weeks)</td>
<td>15.6</td>
<td>14.3-16.8</td>
<td>14.8</td>
<td>14.4-15.2</td>
<td>0.3041</td>
</tr>
<tr>
<td>Parity</td>
<td>1.7</td>
<td>1.2-2.1</td>
<td>1.5</td>
<td>1.4-1.6</td>
<td>0.4895</td>
</tr>
<tr>
<td>Weight (Kg)</td>
<td>73.4</td>
<td>67.5-79.4</td>
<td>65.3</td>
<td>63.7-67.0</td>
<td>0.0043</td>
</tr>
<tr>
<td>BMI (Kg/m²)</td>
<td>28.1</td>
<td>26.2-30.0</td>
<td>25.6</td>
<td>25.0-26.1</td>
<td>0.0159</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>113.1</td>
<td>108.9-117.4</td>
<td>112.0</td>
<td>111.0-113.4</td>
<td>0.6375</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>71.0</td>
<td>67.9-74.2</td>
<td>68.3</td>
<td>67.4-69.3</td>
<td>0.0970</td>
</tr>
</tbody>
</table>

BMI-Body Mass Index, SBP-Systolic Blood Pressure, DBP-Diastolic Blood Pressure, Kg-Kilograms, M²-Meter square (*independent student t-test for differences in means between two groups)
In a univariate Cox proportional regression model, the factors associated with a significant hazard of developing pre-eclampsia during the gestational follow up time were previous history of pre-eclampsia (HR=5.5, 95% CI: 1.9-16.0) and BMI at booking of ≥ 25 kg/m² (HR=3.8, 95% CI: 1.5-10.1). Previous history of miscarriage, HIV infection, history of infertility and parity were not significant risk factors for the development of pre-eclampsia. In the final multivariate Cox regression model including previous history of pre-eclampsia, BMI category ≥ 25 kg/m², and parity (Nulliparous); previous history of pre-eclampsia (HR=7.9; 95% CI: 2.5-25.0) and BMI ≥ 25 kg/m² (HR=4.6; 95% CI: 1.7-12.5) were independently associated with significant hazard of developing pre-eclampsia (Table 3).

Table 2. Cohort analysis of risk factors for development of Preeclampsia

<table>
<thead>
<tr>
<th>Exposure variable</th>
<th>Developed PET</th>
<th>Did not develop PET</th>
<th>Risk Ratio (RR)</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous PET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>4</td>
<td>6</td>
<td>5.1</td>
<td>2.2-12.1</td>
<td>0.0004</td>
</tr>
<tr>
<td>No</td>
<td>23</td>
<td>274</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous Miscarriage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>8</td>
<td>91</td>
<td>0.9</td>
<td>0.4-1.9</td>
<td>0.7422</td>
</tr>
<tr>
<td>No</td>
<td>19</td>
<td>189</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parity category</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nulliparity</td>
<td>14</td>
<td>151</td>
<td>0.9</td>
<td>0.5-1.9</td>
<td>0.8341</td>
</tr>
<tr>
<td>≥1</td>
<td>13</td>
<td>129</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>History of infertility</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>4</td>
<td>21</td>
<td>2.0</td>
<td>0.7-5.2</td>
<td>0.1844</td>
</tr>
<tr>
<td>No</td>
<td>23</td>
<td>259</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV status</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>2</td>
<td>13</td>
<td>1.5</td>
<td>0.4-5.9</td>
<td>0.5342</td>
</tr>
<tr>
<td>Negative</td>
<td>25</td>
<td>267</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI Category</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 25 kg/m²</td>
<td>22</td>
<td>138</td>
<td>3.9</td>
<td>1.5-10.0</td>
<td>0.002</td>
</tr>
<tr>
<td>&lt; 25 kg/m²</td>
<td>5</td>
<td>142</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3. Univariate and multivariate Cox regression of the factors associated with hazard of developing preeclampsia in the cohort

<table>
<thead>
<tr>
<th>Exposure variable</th>
<th>Unadjusted HR (95% CI)</th>
<th>P-Value</th>
<th>Adjusted HR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous preeclampsia</td>
<td>5.5 (1.9-16.0)</td>
<td>0.002</td>
<td>7.9 (2.5-25.0)</td>
<td>0.001</td>
</tr>
<tr>
<td>BMI ≥ 25kg/m2</td>
<td>3.8 (1.5-10.1)</td>
<td>0.007</td>
<td>4.6 (1.7-12.5)</td>
<td>0.003</td>
</tr>
<tr>
<td>Parity (Nulliparous)</td>
<td>0.9 (0.4-2.0)</td>
<td>0.841</td>
<td>1.6 (0.7-3.6)</td>
<td>0.281</td>
</tr>
<tr>
<td>Previous miscarriage</td>
<td>0.8 (0.4-1.8)</td>
<td>0.585</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HIV positive</td>
<td>1.5 (0.3-6.2)</td>
<td>0.601</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>History of infertility</td>
<td>2.0 (0.6-6.9)</td>
<td>0.253</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

HR (Hazard Ratio); BMI (Body Mass Index)

Similarly, Fig. 2 and 3 respectively shows the Kaplan-Meier failure estimates of the cumulative incident probability for developing pre-eclampsia for women with history of previous pre-eclampsia and those with BMI ≥ 25 kg/m² at booking.
Fig. 2. Kaplan-Meier of cumulative incident probability of developing PET among pregnant women with previous history compare to those with no previous history of PET during gestational follow up (Log-rank p-value=0.001)

Legend: Prev_pet=0 (No previous history of PET); pre_pet=1 (previous history of PET)

Fig. 3. Kaplan-Meier of cumulative incident probability of developing PET among pregnant women with overweight or obese BMI compare to those with normal or underweight BMI during gestational follow up (Log-rank p-value=0.003)

Legend: bmi_cat=0 (normal or underweight); bmi_cat=1 (overweight or obese)
Discussion
In this single institutional open cohort study of normotensive singleton pregnant women enrolled at ≤ 20 weeks of gestation, we found the incidence of pre-eclampsia of 8.8% or 87.9 cases per 1,000 pregnancies. We also found that women with previous history of pre-eclampsia and body mass index of > 25 kg/m² estimated at ≤ 20 weeks of gestation had a significantly higher risk and hazard of developing pre-eclampsia during the gestational follow up time.

The relatively high incidence in our cohort reflects the growing burden of pre-eclampsia in Nigeria and most developing countries. The reported incidence of pre-eclampsia varies from one setting to another ranging between 3-5% in most industrialized countries and 2-10% world-wide. A large multi-center cohort study of healthy nulliparous women with singleton pregnancies found an incidence of pre-eclampsia of 5.3%. The variation in incidence has been linked to variation in season of study, gestational age at diagnosis and severity of PET. Also, there is generally a higher prevalence of pre-eclampsia in developing countries compared to developed industrialized countries of the world with a reported prevalence ranging between 2% and 16.7% in Nigeria. Our findings confirm the high burden of this significant cause of maternal and neonatal morbidity and mortality in our population and the need to design and implement best strategies to improve outcome.

There are limited longitudinal studies focusing on the incidence of pre-eclampsia in Nigeria. The few longitudinal studies estimated the incidence of hypertensive disease in pregnancy in general and also the incidence of pre-eclampsia. The study done in a core Northern setting found an overall incidence of hypertensive disorder in pregnancy of 17% and incidence of pre-eclampsia was 6%. Similarly, the cohort study done in a South Western Nigerian population focusing on the influence of duration of sexual cohabitation on the risk of hypertension in nulliparous parturient found an incidence of 28.93% for gestational hypertension and 4.13% for pre-eclampsia. The slight variation in the incidence of pre-eclampsia reported in the North-Western population of 6%, the South-Western population of 4.13% compared to our finding of 8.8% in the North-Central population shows the diversity of our population characteristics within the country. The differences could also be explained by the sample sizes and the fact that previous studies focused on nulliparous women only.

Our study included women of all parity categories and unlike previous reports showing nulliparity as a significant risk factor for pre-eclampsia, our data did not show a significant difference in the risk of pre-eclampsia with parity. The significant risk factors for the development of pre-eclampsia in our cohort were previous history of pre-eclampsia and a BMI ≥ 25kg/m² estimated at ≤ 20 weeks of gestation. Women with previous history of pre-eclampsia had a five times greater risk of developing PET compared to those with no prior history (RR=5.1, 95% CI: 2.2-12.1). Studies including only nulliparous women will miss this important risk factor. However, even in nulliparous women, those with a family history of pre-eclampsia have been noted to have a significant risk of developing the disease. A similar study done in Northern Nigeria found that previous history of pre-eclampsia was associated with a four-fold greater risk of development of PET compared to those with no prior history. Also, women who were overweight or obese at ≤ 20 weeks gestation were about four-fold greater risk of developing PET in the course of gestation compared to those who were of normal weight or underweight (RR=3.9, 95% CI: 1.5-10.0).

The impact of maternal obesity and adverse pregnancy outcomes have been documented and a recent systematic review and meta-analysis on maternal body mass index and risk of birth and maternal health outcomes in low-and middle-income countries further confirms the attributable risk of maternal overweight and obesity with adverse maternal health outcomes. The systematic review and meta-analysis showed that compared with mothers with normal BMI, overweight or obese mothers were at increased odds of gestational diabetes, pregnancy induced hypertension, pre-eclampsia, caesarean section and postpartum hemorrhage. The study results suggested that preventing maternal obesity in the population could reduce the burden of gestational diabetes, pregnan-
cy induced hypertension and pre-eclampsia by 14-35%19. Epidemiologic studies done in Nigeria have also documented that maternal obesity is a significant predictor of pre-eclampsia in our population14,16. Our study findings further lend credence for health education on pre-pregnancy weight control as a strategy for improving maternal and perinatal outcome. It also supports the practice of routine screening for personal history of pre-eclampsia and BMI among risk factors for development of pre-eclampsia as recommended in the National Institute for Health and Clinical Excellence clinical guidelines for antenatal care for healthy pregnant women20. Indeed, a recent committee opinion of the American College of Obstetricians and Gynecologist (ACOG) supports that screening for pre-eclampsia with detailed history risk assessment is currently the best and only recommended screening approach for pre-eclampsia21.

The risk assessment approach based on identified epidemiologic risk factors is important for decision making to implement early those interventions that are effective for preventing pre-eclampsia. For instance, women with identified risk factors for pre-eclampsia have been shown to benefit from early intervention with low-dose aspirin started at or before 16 weeks of gestation22. This systematic review and meta-analysis22, demonstrated that starting low-dose aspirin at ≤ 16 weeks gestation had significant reduction in pre-eclampsia by 53% with a pooled relative risk of 0.47, 95% confidence interval 0.34-0.65 in the intervention compared to placebo. Low-dose aspirin also significantly reduce risk of intrauterine growth restriction with a pooled relative risk of 0.44; 95% CI: 0.30-0.6522. Additionally, a recent guideline issued by the US Preventive Service Task Force recommended the use of low-dose aspirin after 12 weeks of gestation in women with high risk factors for pre-eclampsia23.

It is worth noting that 32.6% of our study cohort reported past history of miscarriage. The proportion of pregnant women with this past pregnancy event was similar to the 29.64% documented in a previous study in South Western Nigeria15. Our data showed that previous history of abortion/miscarriage did not significantly affect the risk of developing pre-eclampsia (Table 2 and 3). Similar findings have been reported in Nigeria15, with previous history of abortion having no significant effect on the hazard of pre-eclampsia (HR=1.05, 95% CI: 0.82-1.35). However, sub-group analysis showed same paternity abortion had a significant protective effect (HR=0.71, 95% CI: 0.55-0.93) on pre-eclampsia15. The clinical implication of the possible epidemiologic association of previous abortion/miscarriage with development of pre-eclampsia requires further investigation.

The major strength of our study is the cohort design with longitudinal follow up data from enrollment to development of outcome. Although our study was done in a single institution in Jos Nigeria, we feel that the cosmopolitan nature of our clinical setting allows for generalizability of our findings to the population of women in most North-Central region of Nigeria. Also, given the large differences in incidence of PET between the BMI categories, and other risk factors in our study sample, our sample size of 307 pregnant women who completed the follow up provided more than 80% statistical power to detect the effect sizes found in our study. We hope a future larger multi-center cohort study may confirm our findings and improve the certainty of our statistical estimates. However, we acknowledge the relatively poor correlation between the point-of-care dipstick estimation of proteinuria used in this study with the gold standard of a 24-hour urine protein estimation24. Therefore, future studies on pre-eclampsia should use more reliable quantitative methods for estimation of proteinuria other than the qualitative point-of-care dipstick method.

**Conclusion**

We found a relatively high incidence of PET among pregnant women in Jos Nigeria and previous history of the disease and overweight or obese pregnant women have a significant hazard of developing the condition during gestational follow up. Our antenatal care services should be organized to include a screening checklist for identification of pregnant women with these epidemiologic risk factors and others documented in the literature. Primary health care facilities should be supported to do routine screening for these risk factors and those identified should commence low-dose aspirin and get referred to secondary or tertiary health care facilities for close monitoring till delivery.

**Conflict of interest**

The authors have no conflict of interest to declare.
References
20. Royal College of Obstetrician and Gynaecologist. Pregnancy and complex social factors: A model for service provision for pregnant Pregnancy and complex so-


22. Bujold, Emmanuel MD, MSc, Roberge, Stéphanie, MSc, Yves Lacasse, MD, MSc, Marc Bureau, MD, François Audibert, MD, MSc, Sylvie Marcoux, MD, PhD, Jean-Claude Forest, MD, PhD, and Yves Giguère, MD P. Prevention of Pre-eclampsia and Intrauterine. Obstet Gynecol. 2010;116(2):402–14. PubMed.
